The cold chain doesn't usually fail because of a single catastrophic event. It fails at the seams. At the handoff points between partners, in the gaps where accountability is unclear, and in markets where the infrastructure isn't built to support the requirements these products demand.

64% of drug launch delays between 2019 and 2024 were caused by manufacturing issues. Biologics now represent 55% of the clinical pipeline. The industry's pipeline is getting harder to manufacture at the exact moment manufacturing is already the primary reason drugs don't make it to market on time.

Running a clinical trial across multiple countries is a fundamentally different undertaking than a domestic one, and the supply chain complexity that comes with it is one of the most consistently underestimated aspects of global clinical development.

Manufacturing is already the number one reason drugs don't get approved. And the agency responsible for evaluating that manufacturing is experiencing significant leadership turnover and staffing losses. If you're running a biotech supply chain, these two realities are on a collision course.

2026 is one of the most active years for biotech M&A in recent memory. The headlines focus on the science. What they almost never talk about is the supply chain, and what happens to it after the deal closes.

The push to bring pharmaceutical manufacturing back to the U.S. is real. But there's a significant gap between the policy conversation and the operational reality.

There's a point in the life of most biotech companies where the supply chain demands start to outpace the team's capacity. Fractional leadership fills that gap, and it's one of the most effective and underutilized models in the industry.

Every biotech that works with a contract manufacturer has a quality agreement on file. But there's a significant difference between one that protects you and one that just checks a box.

If you're at a pre-commercial biotech, standing up a formal S&OP process can feel like something you'll worry about after approval. But by the time you think you need it, you're already behind.

There's a moment in every biotech's journey when the supply chain shifts from supporting clinical development to preparing for commercial reality — and almost everything about how the organization operates needs to change with it.

Many difficult CMO relationships were set up to fail from the start — not because the CMO was bad, but because the selection process was flawed. Here's what actually matters when choosing a manufacturing partner.

The TSA shutdown is grinding airports to a halt. If you're running a biotech supply chain with the same kind of single-point-of-failure risk, the question isn't whether you'll face your own version of this crisis — it's when.

Across the biotech industry, sponsor-CMO friction is one of the most persistent operational challenges. When your CMO underperforms, it's your patients, your timelines, and your regulatory standing on the line. Here's how to have the hard conversation — without torching the relationship.

Most early-stage biotech companies wait too long to build a real supply chain function — and the ones that don't often build the wrong things first. Here's what the right sequencing looks like and the three decisions that matter most in year one.